<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03979274</url>
  </required_header>
  <id_info>
    <org_study_id>MS200125_0008</org_study_id>
    <nct_id>NCT03979274</nct_id>
  </id_info>
  <brief_title>A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers</brief_title>
  <official_title>Prospective, Single Dose, Randomized, Open Label, Comparative, Cross-study to Establish Bioequivalence Between the New Formulation and the Approved Formulation for Levothyroxine (Eutirox® From Merck, S. A. de C. V.) Given as 3 Tablets of 200 μg p.o. in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the bioequivalence between the new and the approved formulation
      for levothyroxine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2019</start_date>
  <completion_date type="Actual">January 13, 2020</completion_date>
  <primary_completion_date type="Actual">January 13, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Serum Concentration In Pre Dose Corrected Data (Cmax[aj]) of levothyroxine (T4)</measure>
    <time_frame>Pre-dose to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Curve of Serum Concentration From Time Zero Until The Last Sampling Time In Pre Dose Corrected Data (AUC0-t [aj]) of levothyroxine (T4)</measure>
    <time_frame>Pre-dose to 48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Serum Concentration (tmax) of Levothyroxine (T4)</measure>
    <time_frame>Pre-dose to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (t1/2) of Levothyroxine (T4)</measure>
    <time_frame>Pre-dose to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Curve of the Serum Concentration as a Function of Time, From Time Zero Until The Last Sampling Time (AUC0-t)) of Levothyroxine (T4)</measure>
    <time_frame>Pre-dose to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Levothyroxine (T4)</measure>
    <time_frame>Pre-dose to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in Physical Examination, Vital Signs, Laboratory Parameters and Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to Day 37</time_frame>
    <description>Number of Participants With Clinically Significant Abnormalities in Physical Examination, Vital Signs, Laboratory Parameters and Electrocardiogram (ECG) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AE)</measure>
    <time_frame>Baseline up to Day 38</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Reference Eutirox®, then Test Eutirox®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) in treatment period 1 followed by single oral dosing of Test Eutirox® 600 microgram (3 tablets of 200 microgram) in treatment period 2. Each treatment period will be separated by a 35-day wash-out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Eutirox®, then Reference Eutirox®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose of test Eutirox® 600 microgram (3 tablets of 200 microgram) in treatment period 1 followed by single oral dosing of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) in treatment period 2. Each treatment period will be separated by a 35-day wash-out period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference Eutirox®</intervention_name>
    <description>Participants will receive single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.</description>
    <arm_group_label>Reference Eutirox®, then Test Eutirox®</arm_group_label>
    <arm_group_label>Test Eutirox®, then Reference Eutirox®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test Eutirox®</intervention_name>
    <description>Participants will receive single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.</description>
    <arm_group_label>Reference Eutirox®, then Test Eutirox®</arm_group_label>
    <arm_group_label>Test Eutirox®, then Reference Eutirox®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who have provided their written consent prior to any study-related
             activity

          -  Ethnic origin: Mexicans

          -  Body mass index from 18 to 27 kilogram per meter square (kg/m^2)

          -  Normal vital signs (includes heart rate between 50 and 100 beats per minute,
             respiratory rate between 12 and 20 per minute, systolic blood pressure between 80 and
             129 milimeter of mercury (mmHg) , diastolic blood pressure between 50 and 80 mmHg and
             temperature between 36.0 degree celsius and 37.0 degree celsius. The measurement will
             be made according to the instructive BE-IT-005 Medición de signos vitales)

          -  Normal electrocardiogram [ECG]. No abnormalities are allowed, even though they are not
             relevant (PR, QRS, QT, QTcF should be within normal range; no conduction abnormalities
             are allowed, etcetera (etc)

          -  All values in blood and urine tests should be within the normal range or showing no
             clinically relevant deviation as judged by the Investigator

          -  Participants with thyroid panel results within normal range (T3 and T4 total and free,
             as well as thyroid-stimulating hormone (TSH) should be within the normal range)

          -  Non-smoker at least in the last 3 months

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participation in the clinical study within 90 days prior to the first dose of the
             study drug

          -  History of hypersensitivity to the study drug or its excipients

          -  History or current asthma or any severe allergy (which requires hospitalization or
             prolonged therapy), allergy or intolerance to any food that, in the opinion of the
             investigator, poses a safety risk (allergy to iodine)

          -  History of cardiovascular, renal, liver, metabolic, gastrointestinal, neurological,
             endocrine, hematopoietic (any type of anemia) conditions, mental disorder or organic
             abnormalities that may affect the pharmacokinetic study of the study drug

          -  Any medical or surgical condition, including findings in the medical history or
             clinical assessment prior to the study, that in the opinion of the investigator poses
             a risk or contraindication for the participants participation in the study and may
             affect the study objectives, conduct or analysis

          -  History or presence of alcohol abuse (average daily intake not higher than 3 units or
             weekly intake not higher than 21 units; 1 unit is equivalent to 340 mililiter (mL) of
             beer, 115 mL of wine or 43 mL of prepared drinks), psychoactive substances or chronic
             use of drugs

          -  Participants who have been exposed to agents knows by inducing or inhibiting the liver
             enzymatic systems or who have taken potentially toxic drugs within the last 30 days to
             the study start-up

          -  Participants who take drugs affecting the metabolism of the thyroid hormone, such as:
             oral contraceptives, hormonal implants, parenteral hormones, steroids, anabolic drugs,
             androgens, etc., or any drug affecting the levothyroxine's bioavailability such as the
             proton pump inhibitors or multivitamins, nutritional supplements or herbal products
             that may affect the study, except for the occasional use of paracetamol

          -  Participants who have been hospitalized for any reason within the 60 days prior to the
             study start-up or who have been severely ill within the last 30 days prior to the
             study start-up

          -  Participants who have donated or lost 450 mL of blood within the last 60 days prior to
             the study start-up

          -  Participants non- smokers, who have smoked tobacco, cigarettes or consumed coffee,
             snuff or drinks containing xanthines such as caffeine, (tea, cocoa, chocolate, matte,
             cola, etc.) theobromine, theophylline, among others, affecting the pharmacokinetics of
             the drug in assessment, drinking alcohol, or charcoal-grilled foods consumed within
             twenty-four hours prior to administration the dose of medication

          -  Screening biosafety positive tests for the human immunodeficiency virus (HIV),
             hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis Venereal Disease
             Research Laboratory (VDRL)

          -  Positive result in the abuse drugs screening tests, such as: amphetamines,
             benzodiazepines, cocaine, methamphetamines, morphine and tetrahydrocannabinoids

          -  Presence of alcohol in breath test

          -  Women pregnancy positive tests (qualitative and quantitative) at the screening and
             inclusion in each period

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cecype, Fray Bernardino de Sahagún</name>
      <address>
        <city>Morelia - Michoacan</city>
        <zip>58249</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eutirox</keyword>
  <keyword>Levothyroxine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.merckgroup.com/en/research/our-approach-to-research-and development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

